Critical evaluation of the use of dogs in biomedical research and testing

Altex

Volumn 28, Issue 4, 2011, Pages 355-359

  Zurlo, Joanne ^a   Bayne, Kathryn A ^b   Brown, Dorothy Cimino ^c   Burkholder, Tanya H ^d   Dellarco, Vicki L ^e   Ellis, Amy ^f   Garrett, Laura ^g   Hubrecht, Robert ^h   Janus, Erik R ⁱ   Kinter, Lewis B ^j   Luddy, Elizabeth ^f   Meunier, LaVonne D ^k   Scorpio, Diana G ^l,n   Serpell, James A ^c   Todhunter, Rory J ^m  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b AAALAC International   (United States)

^c UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^h Universities Federation for Animal Welfare   (United Kingdom)

ⁱ LLP   (United States)

^j ASTRAZENECA   (United Kingdom)

^k GLAXOSMITHKLINE   (United States)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m Animal Health Diagnostic Center   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PESTICIDE; RESINIFERATOXIN; SULFANILAMIDE;

ALPORT SYNDROME; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TESTING ALTERNATIVE; ANIMAL TESTING REDUCTION; ANIMAL TESTING REFINEMENT; ANIMAL TESTING REPLACEMENT; ASTHMA; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BONE CANCER; CARDIOMYOPATHY; CHRONIC PAIN; CHRONIC TOXICITY; CONFERENCE PAPER; DOG; DOG DISEASE; DRUG APPROVAL; DRUG FATALITY; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; FOOD AND DRUG ADMINISTRATION; FOOD SAFETY; GENE MUTATION; GENE THERAPY; GENETIC DISORDER; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LEUKOCYTE ADHESION DEFICIENCY; MEDICAL RESEARCH; NARCOLEPSY; NONHUMAN; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RETINITIS PIGMENTOSA; TOXICITY TESTING; VETERINARY MEDICINE; VON WILLEBRAND DISEASE;

EID: 84455189541     PISSN: 09467785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. Bauer, T. R. Jr, Adler, R. L., and Hickstein, D. D. (2009). Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems. ILAR J. 50, 168-186.
2. ICH - International Council on Harmonization (2010). Guidance for Industry M3 - Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073246.pdf
3. th ed.). Washington DC: National Academy Press.
4. st century - A vision and a strategy. Washington DC: National Academies Press.
5. th ed.) Washington DC: National Academies Press.
6. Nichols, T. C., Dillow, A. W., Franck, H. W. G., et al. (2009). Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von Willebrand disease, and Factor VII deficiency. ILAR J. 50, 144-167.
7. Olson, H., Betton, G., Robinson, D., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Reg. Toxicol. Pharmacol. 32, 56-67.
8. Serpell, J. A. (2003). Anthropomorphism and anthropomorphic selection: Beyond the "cute" response. Soc. Anim. 11, 83-100.